GR Foster

1405 ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY

Jean–Michel Pawlotsky, S.K. Sarin, GR Foster et al. · Journal of Hepatology · 2012 · 42 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials

Michael Gschwantler, GR Foster, I.M. Jacobson et al. · Zeitschrift für Gastroenterologie · 2014 · 30 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials

Massimo Puoti, C. Cooper, Sulkowski et al. · Queen Mary Research Online (Queen Mary University of London) · 2014 · 22 citations

Medicine, Infectious Diseases, Pharmacology +14

Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials

J. Grebley, Massimo Puoti, Heiner Wedemeyer et al. · Journal of Hepatology · 2017 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +15